P1vital Ltd., Wallingford, Oxfordshire, UK.
Department of Psychiatry, VU University Medical Center/GGZ in Geest, A.J. Ernststraat 1187, 1081 HL Amsterdam, The Netherlands.
Neurosci Biobehav Rev. 2019 Feb;97:87-93. doi: 10.1016/j.neubiorev.2018.06.019. Epub 2018 Jun 22.
Trans-diagnostic, domain- or symptom-focused approaches have been heralded as advancing psychiatric research, but relatively few clinical research programmes have been undertaken to leverage their potential. In this manuscript we describe the approach and protocol for an exploratory study, PRISM (Psychiatric Ratings using Intermediate Stratified Markers), that will be conducted to explore the biomarkers in schizophrenia (SZ) and Alzheimer's Disease (AD) that may be related to a common symptom, social withdrawal. Patient participants (N = 72 SZ and N = 72 AD study completers), will complete a series of fMRI, EEG, and behavioural paradigms, as well as contributing blood-derived (e.g. epigenetic) and smartphone data related to social behaviour. Self- as well as caregiver- and researcher-reported assessments will be provided to characterise social withdrawal. Normative data will also be collected from a group of healthy controls (N = 48 study completers), half of whom will be matched in terms of age and gender distribution to the SZ and AD group, respectively. Thus we will explore both differentiation and cross-diagnostic overlap in the biomarkers associated with different levels of social withdrawal in SZ and AD. In this way we aim to provide a deeper understanding of the biological underpinnings of symptomatology common to both disorders, and provide insights into novel treatment targets and future drug development approaches.
跨诊断、领域或症状为重点的方法被认为是推进精神医学研究的方法，但相对较少的临床研究计划利用了它们的潜力。在本文中，我们描述了一项探索性研究 PRISM（使用中间分层标志物进行精神病学评估）的方法和方案，该研究将探索可能与共同症状（社交退缩）相关的精神分裂症（SZ）和阿尔茨海默病（AD）的生物标志物。患者参与者（N=72 名 SZ 和 N=72 名 AD 研究完成者）将完成一系列 fMRI、EEG 和行为范式，以及与社交行为相关的血液衍生（如表观遗传）和智能手机数据。将提供自我报告以及护理人员和研究人员报告的评估，以描述社交退缩。还将从一组健康对照组（N=48 名研究完成者）中收集正常数据，其中一半将根据年龄和性别分布与 SZ 和 AD 组分别匹配。因此，我们将探索 SZ 和 AD 中不同程度的社交退缩与生物标志物的分化和跨诊断重叠。通过这种方式，我们旨在更深入地了解两种疾病共有的症状学的生物学基础，并为新的治疗靶点和未来的药物开发方法提供见解。
